Novel use of 2h-benzimidazol-2-one, 1,3-Dihydro-1-(2{4-[3-(trifluoromethyl)phenyl]-1-piperazinyl}ethyl)-and its physiologically acceptable addition salts

• US 20040180904A1
• Filed: 05/04/2004
• Published: 09/16/2004
• Est. Priority Date: 05/11/2001
• Status: Active Grant

• Current Assignee: Jurgen K. Beck
• Original Assignee: Jurgen K. Beck
• Inventors: Beck, Jurgen K.
• Granted Patent: US 8,030,314 B2
• Time in Patent Office: Days
• US Class Current: 514/254.06
• CPC Class Codes: A61K 31/495 having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazinesA61K31/48 takes precedence ; with three nitrogen atoms A61K31/53
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs

Abstract

Use of 2H-benzimidazol-2-one, 1,3-dihydro-1-(2{4-[-(trifluoromethyl)phenyl]-1-piperazinyl}ethyl)- or a physiologically acceptable acid addition salt thereof, for the manufacture of a medicament for the treatment of extrapyramidal movement disorders. These extrapyramidal movement disorders may result from idopathic Parkinson'"'"'s disease, from the adverse effects of the administration of anti-Parkinson drugs in idiopathic Parkinson'"'"'s disease, from dyskinesias caused by idiopathic Parkinson'"'"'s disease and/or long-term administration of anti-Parkinson drugs, from Parkinson-like or Parkinson-related syndromes of from Parkinsonoid symptomes. Another aspect of the present invention concerns a pharmaceutical composition comprising, as active ingredients-(I) 2H-benzimidazol-2-one, 1,3-dihydro-1-(2-{4-[3-(trifluoromethyl)phenyl]-1-piperazinyl}ethyl)-or a physiologically acceptable acid addition salt thereof, and (II) at least one anti-Parkinson drug, in combination with one or more pharmaceutically acceptable excipients.

Claims

1. Use of 2H-benzimidazol-2-one, 1,3-dihydro-1-(2-{4-[3-(trifluoromethyl)phenyl]-1-piperazinyl}ethyl)- or a physiologically acceptable acid addition salt thereof, for the manufacture of a medicament for the treatment of extrapyramidal movement disorders.

2. Use according to claim 1,

for the treatment of extrapyramidal movement disorders resulting from idiopathic Parkinson'"'"'s disease.

3. Use according to claim 1,

for the treatment of extrapyramidal movement disorders arising as adverse effects of the administration of anti-Parkinson drugs in idiopathic Parkinson'"'"'s disease.

4. Use according to claim 3,

for the treatment of extrapyramidal movement disorders in the form of dyskinesias caused by idiopathic Parkinson'"'"'s disease and/or long-term administration of anti-Parkinson drugs.

5. Use according to claim 1,

for the treatment of extrapyramidal movement disorders related to Parkinson-like or Parkinson-related syndromes or to Parkinsoid symptomes.

6. Use according to claim 5,

for the treatment of extrapyramidal movement disorders arising as adverse effects of the administration of anti-Parkinson drugs and similar drugs in the treatment of said Parkinson-like or Parkinson-related syndromes, or said Parkinsoid symptomes.

7. Use according to claim 5 or 6,

wherein

said extrapyramidal movement disorders related to Parkinson-like or Parkinson-related syndromes include dyskinetic syndromes, dystonic syndromes, priming of motor disturbances and other kinds of motoric fluctuations, multi-systems atrophy, progressive supranuclear palsy, corticobasalic degeneration, olivio-ponto cerebellar atrophy, Shy-Drager-syndromes and similar syndromes.

8. Use according to claim 7,

wherein

said dystonic syndromes include spastic torticollis, tic diseases, blepharospasm (Meige syndrome) and similar syndromes.

9. Use according to claim 5,

wherein

said extrapyramidal movement disorders provoking said Parkinsoid symptomes include adverse effects caused by the administration of neuroleptic drugs and antiemetics/prokinetic drugs.

10. Use according to claim 1,

for the treatment of extrapyramidal movement disorders provoking symptomes such as several types of tremor and/or symptomes related to Gilles de la Tourette syndrome, restless legs syndrome, ballism, myoclonus and Wilson'"'"'s disease.

11. Use according to claim 1,

for the treatment of extrapyramidal movement disorders accompanied with chorea and choreatic syndromes, such as Huntington'"'"'s disease, chorea minor and pregnancy related chorea.

12. Use according to anyone of the claims 10 or 11,

for the treatment of extrapyramidal movement disorders caused or enhanced by the aministration of medicaments intended for the treatment of chorea and choreatic syndromes, such as Huntington'"'"'s disease, chorea minor and pregnancy related chorea, several types of tremor, Gilles de la Tourette syndrome, restless legs syndrome, ballism, myoclonus and Wilson'"'"'s disease.

13. Use according to claim 1,

for the treatment of extrapyramidal movement disorders resulting from tardive dyskinesia in chronic schizophrenic patients.

18. Use according to anyone of the claims 1 to 17,

wherein

2H-benzimidazol-2-one, 1,3-dihydro-1-(2-{4-[3-(trifluoromethyl)phenyl]-1-piperazinyl}ethyl)- is in the form of its physiologically acceptable acid addition salt formed with hydrochloric acid, sulfuric acid, maleic acid or fumaric acid.

14. Use of 2H-benzimidazol-2-one, 1,3-dihydro-1-(2-{4-[3-(trifluoromethyl)phenyl]-1-piperazinyl}ethyl)- or a physiologically acceptable acid addition salt thereof in combination with at least one conventional anti-Parkinson drug for the manufacture of a pharmaceutical combination preparation for the treatment of extrapyramidal movement disorders caused by idiopathic Parkinson'"'"'s disease or for the treatment of Parkinson-like or Parkinson-related syndromes or Parkinsoid symptomes and/or for relief of the adverse effects of the administration of anti-Parkinson drugs.

15. Use according to claim 14,

wherein

said at least one anti-Parkinson drug is selected from a group including levodopa, amantadine, biperiden, metixen, budipine, metoclopramid, selegiline and/or at least one conventional dopamine agonist.

16. Use according to claim 15,

wherein

said conventional dopamine agonist include apomorphine, bromocriptine, α

-dihydro-ergocriptine, cabergoline, lisuride, pergolide, promipexol and ropinirol.

17. Use according to claim 14,

wherein

said conventional anti-Parkinson drug includes a dopa decarboxylase blocking agent such as for example benserazid or carbidopa.

19. A pharmaceutical composition comprising, as active ingredients

(I) 2H-benzimidazol-2-one, 1,3-dihydro-1-(2-{4-[3-(trifluoromethyl)phenyl]-1-piperazinyl}ethyl)- or a physiologically acceptable acid addition salt thereof, and

(II) at least one anti-Parkinson drug,

in combination with one or more pharmaceutically acceptable excipients.

20. The pharmaceutical composition according to claim 19,

wherein

such at least one anti-Parkinson drug is selected from a group including levodopa, amantadine, biperiden, metixen, budipine, metoclopramid, selegiline and/or at least one conventional dopamine agonist.

21. The pharmaceutical composition according to claim 20,

wherein

said conventional dopamine agonist include apomorphine, bromocriptine, α

-dihydro-ergocriptine, cabergoline, lisuride, pergolide, promipexol and ropinirol.

22. Use according to claim 20,

wherein

said conventional anti-Parkinson drug includes a dopa decarboxylase blocking agent such as for example benserazid or carbidopa.

23. The pharmaceutical composition according to anyone of the claims 19 to 22

wherein

2H-benzimidazol-2-one, 1,3-dihydro-1-(2-{4-[3-(trifluoromethyl)phenyl]-1-piperazinyl}ethyl)- is in the form of its physiologically acceptable acid addition salt formed with hydrochloric acid, sulfuric acid, maleic acid or fumaric acid.